Olaparib (LynparzaTM), a poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor, is approved (tablet formulation) for treatment in the maintenance setting for patients with platinum-sensitive relapsed ovarian cancer, irrespective of BRCA1/2 mutation (BRCAm) status.10,11. Here, BRCA1 is linked to ovarian cancer.